Induced Pluripotent Stem Cells News and Research

RSS

CDI, iPS Academia Japan announce licensing agreement for seminal iPSC patent portfolio

Cellular Dynamics International, Inc. (CDI), the world's largest producer of cellular tools for drug discovery and safety derived from induced pluripotent stem cells (iPSCs), and iPS Academia Japan, Inc., today announced a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka, M.D., Ph.D., Center for iPS Cell Research and Application (CiRA), Kyoto University.

7 May 2010

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian, Inc., the leading company focused on creating new therapeutics discovered using cellular reprogramming and directed differentiation of patient cells, today announced that it has been awarded a three-year $1.5 million "Basic Biology Award" from the California Institute of Regenerative Medicine.

30 Apr 2010

UC Irvine scientists receive CIRM grants for stem cell research

Two UC Irvine scientists will receive grants totaling more than $2.6 million to study the underlying biology of stem cells aimed at treating spinal cord injury, cancer and other disorders.

30 Apr 2010

New reprogramming strategies needed for production of iPSCs: Study

Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. In a study that will appear in the journal Nature and is receiving early online release, investigators from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute (HSCI), describe finding that an important cluster of genes is inactivated in induced pluripotent stem cells (iPSCs) that do not have the full development potential of embryonic stem cells.

26 Apr 2010

CDI's iCell Cardiomyocytes named to MIT Technology Review's Annual 10 Emerging Technologies List

Cellular Dynamics International (CDI) today announced that CDI's development and commercialization of human cardiomyocytes for drug discovery and toxicity testing, based on the work of CDI co-founder and chief scientific officer, James A. Thomson, Ph.D., on induced pluripotent stem cell (iPSCs) technology, have been named to the MIT Technology Review's Annual 10 Emerging Technologies List.

21 Apr 2010

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Researchers in China are reporting that they have found a way to determine which somatic cells -- or differentiated body cells -- that have been reprogrammed into a primordial, embryonic-like state are the most viable for therapeutic applications.

17 Apr 2010

Stem cell scientists receive stimulus grants to study lung and blood disorders

Stem cell scientists at The University of Texas Health Science Center at Houston (UTHealth) were awarded stimulus grants totaling almost $2 million to research experimental treatments for blood disorders and inherited lung diseases affecting children.

13 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Human amniotic fluid skin cells "reprogrammed" to pluripotency

In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.

16 Mar 2010

Keynote speakers to discuss regenerative medicine therapies at upcoming forum

What regenerative medicine therapies are being applied to patients today? What hurdles stand between stem cell therapies and real treatments in the clinic? Keynote speakers at the upcoming inaugural Translational Regenerative Medicine Forum will discuss these topics as well as provide an update on various national and regional stem cell initiatives.

16 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

The United States government's decision last year to lift restrictions on federally-funded stem cell research has helped the nation's stem-cell researchers concentrate on science, but limitations remain - even under the new policy, according to George Daley, a Howard Hughes Medical Institute investigator at Children's Hospital Boston.

22 Feb 2010

ACT's research on therapeutic cell types obtained from iPS cells featured in leading news media outlets

Advanced Cell Technology or “ACT” announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.

17 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

14 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

Stanford researchers use DNA minicircles to induce pluripotency in stem cells from human fat

Tiny circles of DNA are the key to a new and easier way to transform stem cells from human fat into induced pluripotent stem cells for use in regenerative medicine, say scientists at the Stanford University School of Medicine. Unlike other commonly used techniques, the method, which is based on standard molecular biology practices, does not use viruses to introduce genes into the cells or permanently alter a cell's genome.

8 Feb 2010

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

In the 7 Feb. 2010 issue of the journal Nature, scientists at the Genome Institute of Singapore (GIS), report that a genetic molecule, called Tbx3, which is crucial for many aspects of early developmental processes in mammals, significantly improves the quality of stem cells that have been reprogrammed from differentiated cells.

7 Feb 2010

International Stem Cell opens new cell production facility in Oceanside, California

International Stem Cell Corporation, www.internationalstemcell.com, announced today that its new cell production facility has passed final building inspection, which will enable development and manufacturing of the company and its partners’ clinical-grade stem cell products.

5 Feb 2010